IDEXX Laboratories Announces Third Quarter Results
Business Wire•02/11/2026•06:30 ET
0
Key Highlights
- ➤Q3 revenue $1.214 billion, up 10% reported and organically
- ➤Q3 EPS $4.01, up 18% reported and 22% comparable
- ➤2026 revenue guidance raised to $4,741-$4,767 million
- ➤2026 EPS outlook raised to $14.96-$15.16
- ➤Over 1,900 IDEXX inVue Dx analyzers placed, installed base nears 11,000
Expert Statements
Mike Erickson, President and Chief Executive Officer of IDEXX Laboratories
“IDEXX delivered exceptional third quarter results, reflecting strong commercial execution and momentum from our innovation-driven growth strategy.”
Mike Erickson, President and Chief Executive Officer of IDEXX Laboratories
“Innovations like IDEXX inVue Dx with FNA, and IDEXX Cancer Dx becoming a multi-cancer panel, are helping practices detect disease earlier and work more efficiently.”
Mike Erickson, President and Chief Executive Officer of IDEXX Laboratories
“In software, we advanced our capabilities with the acquisition of CoVet, an AI clinical assistant that supports veterinary team productivity and diagnostics utilization, creating more value for our customers and shareholders.”
* Achieves third quarter revenue growth of 10% as reported and organic and CAG Diagnostics recurring revenue growth of 11% as reported and organic.
* Double-digit organic revenue growth was led by strong volume expansion, including benefits from IDEXX's innovations and excellent commercial execution.
Get started
Create a free account to read the full story.